Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.

Milan E, Lazzari C, Anand S, Floriani I, Torri V, Sorlini C, Gregorc V, Bachi A.

J Proteomics. 2012 Dec 5;76 Spec No.:91-101. doi: 10.1016/j.jprot.2012.06.022. Epub 2012 Jul 4.

PMID:
22771314
2.

Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.

Lazzari C, Spreafico A, Bachi A, Roder H, Floriani I, Garavaglia D, Cattaneo A, Grigorieva J, Viganò MG, Sorlini C, Ghio D, Tsypin M, Bulotta A, Bergamaschi L, Gregorc V.

J Thorac Oncol. 2012 Jan;7(1):40-8. doi: 10.1097/JTO.0b013e3182307f17.

3.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP.

J Natl Cancer Inst. 2007 Jun 6;99(11):838-46.

PMID:
17551144
4.

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J.

J Clin Oncol. 2009 Jun 1;27(16):2653-9. doi: 10.1200/JCO.2008.17.3930. Epub 2009 May 4.

PMID:
19414683
5.

Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.

Zhao W, Yang Z, Liu X, Tian Q, Lv Y, Liang Y, Li C, Gao X, Chen L.

J Int Med Res. 2013 Jun;41(3):573-83. doi: 10.1177/0300060513476582. Epub 2013 Apr 23.

PMID:
23613495
6.

Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.

Tang C, Gao H, Li X, Liu Y, Li J, Qin H, Wang W, Qu L, An J, Yang S, Liu X.

J Cancer Res Clin Oncol. 2014 Mar;140(3):427-33. doi: 10.1007/s00432-014-1582-x. Epub 2014 Jan 9.

PMID:
24401995
7.

Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.

Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.

Lung Cancer. 2015 Mar;87(3):311-7. doi: 10.1016/j.lungcan.2015.01.004. Epub 2015 Jan 14.

PMID:
25617986
8.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
9.

Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.

Kuiper JL, Heideman DA, Würdinger T, Grünberg K, Groen HJ, Smit EF.

Clin Lung Cancer. 2015 Jan;16(1):60-6. doi: 10.1016/j.cllc.2014.07.008. Epub 2014 Aug 15.

PMID:
25242669
10.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.

Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

Cancer Chemother Pharmacol. 2012 Aug;70(2):315-20. doi: 10.1007/s00280-012-1876-0. Epub 2012 Jul 4.

PMID:
22760226
11.

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.

Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, Lu H, Teegarden P, Weber MR, Belani CP.

J Thorac Oncol. 2008 Mar;3(3):258-64. doi: 10.1097/JTO.0b013e3181653d1b.

12.

Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.

Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, Kira Y, Hirata K.

BMC Res Notes. 2013 Apr 8;6:139. doi: 10.1186/1756-0500-6-139.

13.

Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.

Nishio M, Yamanaka T, Matsumoto K, Kimura H, Sakai K, Sakai A, Sone T, Horiike A, Koizumi F, Kasahara K, Ohira T, Ikeda N, Saijo N, Arao T, Nishio K.

J Thorac Oncol. 2011 Nov;6(11):1889-94. doi: 10.1097/JTO.0b013e3182286d41.

14.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M.

J Natl Cancer Inst. 2005 May 4;97(9):643-55.

PMID:
15870435
15.

Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis.

Sun W, Hu G, Long G, Wang J, Liu D, Hu G.

Curr Med Res Opin. 2014 Oct;30(10):2033-9. doi: 10.1185/03007995.2014.934792. Epub 2014 Jul 9.

PMID:
24926735
16.

Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.

Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, Kohno S.

Cancer Chemother Pharmacol. 2011 Feb;67(2):331-8. doi: 10.1007/s00280-010-1325-x. Epub 2010 Apr 17.

PMID:
20401612
17.

Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib.

Garrisi VM, Bongarzone I, Mangia A, Cremona M, De Bortoli M, Vaghi E, Galetta D, Pastorino U, Quaranta M, Abbate I, Paradiso A.

Clin Biochem. 2011 Jul;44(10-11):936-40. doi: 10.1016/j.clinbiochem.2011.04.013. Epub 2011 Apr 22.

PMID:
21539823
18.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.

Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ.

Lung Cancer. 2009 Jul;65(1):80-4. doi: 10.1016/j.lungcan.2008.10.016. Epub 2008 Dec 6.

PMID:
19059670
19.

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sanchez JJ, Taron M, Rosell R.

Lung Cancer. 2011 Apr;72(1):84-91. doi: 10.1016/j.lungcan.2010.07.008. Epub 2010 Aug 11.

PMID:
20705357
20.

A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.

Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, Kawahara M, Abe H, Yamaguchi T, Akiba J, Takamori S, Hayashi A, Kage M.

Lung Cancer. 2012 Oct;78(1):39-44. doi: 10.1016/j.lungcan.2012.07.002. Epub 2012 Jul 31.

PMID:
22858448

Supplemental Content

Support Center